Machine learning for risk stratification in the emergency department (MARS-ED): a randomized controlled trial

机器学习在急诊科风险分层中的应用(MARS-ED):一项随机对照试验

阅读:2

Abstract

Emergency department (ED) crowding necessitates rapid, accurate risk stratification to optimize care and resource allocation. Traditional clinical prediction tools like NEWS, APACHE II, and SOFA score have limited generalizability or rely on extensive inputs, including vitals. We developed RISK(INDEX), a machine-learning tool predicting 31-day mortality using routine laboratory values, age, and sex. To evaluate the clinical impact of a machine learning-based risk score in routine care, we conducted an investigator-initiated, open-label, randomized, non-inferiority trial (MARS-ED) at the Maastricht University Medical Center+ ED. Adult patients ( ≥ 18 years) assessed by an internal medicine specialist and with ≥4 laboratory tests were eligible. Patients were randomized 1:1 using computer-generated permuted blocks to standard care (n = 659) or standard care plus access to the RISK(INDEX) (n = 644). No blinding was possible because physicians needed to view the RISK(INDEX). The primary outcomes for this study were the prognostic accuracy for 31-day mortality and clinical impact of the RISK(INDEX). In total, 1303 participants were analyzed. RISK(INDEX)'s prognostic accuracy matched or outperformed clinical intuition (AUROC 0.84 vs. 0.73-0.76) and was statistically higher than NEWS, APACHE II, and SOFA prediction tools (AUROC 0.65-0.75). RISK(INDEX) predictions aligned with clinicians' expectations in only about half of cases, with highest discordance among less experienced physicians. Despite its prognostic accuracy, the RISK(INDEX) did not alter treatment plans (1/644 changes; 0.16%) or clinical outcomes, and clinicians perceived low added value. No adverse events related to the intervention occurred, and recruitment was completed as planned. These findings show that prognostic accuracy alone is insufficient to achieve clinical impact in the ED and that user-centered, actionable model design is needed to ensure relevance, trust, and responsiveness. ClinicalTrials.gov registration: NCT05497830.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。